Kinetic Trust Fund Raise of ₹6.6 Cr

Kinetic Trust Board Meeting Date

Kinetic Trust Ltd intimated a Board meeting on 04/11/2026. The agenda includes approval of quarterly financial statements.

Kinetic Trust Other Announcement

Kinetic Trust Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.

Kinetic Trust Q1 FY27 Results: Net Profit ₹0 Cr

Kinetic Trust Ltd reported revenue from operations of ₹0.2 Cr (-33.3% YoY) and net profit of ₹0 Cr for Q1 FY27.

Key figure

Net profit ₹0 Cr

Kinetic Trust Board Meeting Outcome

Kinetic Trust Limited announced the approval of its unaudited standalone financial results for the quarter ended June 30, 2026, during its board meeting.

Kinetic Trust Board Meeting Date

Kinetic Trust Limited scheduled a board meeting on August 12, 2026, to approve the financial results for the quarter ended June 30, 2026.

Kinetic Trust Annual General Meeting

Kinetic Trust Limited conducted its 34th Annual General Meeting on August 7, 2026. Shareholders approved the issuance of 60,00,000 warrants on a preferential basis and increased authorized capital.

Rite Zone Chemcon India Fund Raise of ₹6.58 Cr

Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.

Value

₹6.58 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.